The short-term effectiveness of a two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was widely demonstrated. However, long term effectiveness is still unknown. Leveraging the centralized computerized database of Maccabi Healthcare Services (MHS), we assessed the correlation between time-from-vaccine and incidence of breakthrough infection between June 1 and July 27, the date of analysis. After controlling for potential confounders as age and comorbidities, we found a significant 1.51 fold (95% CI, 1.38–1.66) increased risk for infection for early vaccinees compared to those vaccinated later that was similar across all ages groups. The increased risk reached 2.26- fold (95% CI, 1.80–3.01) when comparing those who were vaccinated in January to those vaccinated in April. This preliminary finding of vaccine waning as a factor of time from vaccince should prompt further investigations into long-term protection against different strains.
A two-dose regimen of the BioNTech/Pfizer mRNA BNT162b2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine was demonstrated to be highly effective in preventing infection and symptomatic COVID-19, both in clinical trials1,2 and real-world settings3,4. However, long-term effectiveness is still unknown. Different studies examined the immunological response over time5,6,7 whereas other smaller cohort studies have analyzed serological response in relation to clinical outcomes8, large-scale studies of a long-term correlate of protection are still needed.
The Delta (B.1.617.2) variant, initially identified in India and now globally detected, is currently the dominant strain in Israel. In light of the recent surge of cases in Israel, many of which among vaccinated individuals11, concerns of reduced vaccine efficacy against the Delta variant have surfaced, including official reports of decreased protection (https://www.gov.il/he/Departments/news/05072021-03). Contrastingly, other studies report only modest differences in vaccine effectiveness12 and substantial antibody response to the Delta variant13.
Data regarding the duration of protection are essential for effective resource allocation and vaccine administration, such as the need and urgency of a third dose14,15. Israel’s rapid rollout of the mass vaccination campaign allows us to investigate the correlation between time-from-vaccine and vaccine effectiveness against the Delta variant.
To this end, we conducted a retrospective cohort study comparing the incidence rates of breakthrough infections and COVID-19-related hospitalization between Early and Late Vaccinees, using data from Maccabi Healthcare Services (MHS), Israel’s second-largest Health Maintenance Organization, which covers 2.5 million members (26.5% of the population) and provides a representative sample of the Israeli population.
Of 1,395,134 MHS members over the age of 16 who received the second dose of the vaccine between January and April of 2021, 1,352,444 were eligible for the study. In all, 27,143 individuals did not receive the second dose according to the guidelines, and 15,547 individuals were tested positive for SARS-CoV-2 prior to the study period.
The incidence rates of breakthrough infections per 10,000 individuals who received their second dose during the months of January, February, March, and April were 36.5 (95% CI 34.8–38.2), 33.65 (95% CI 31.9–35.3), 23.06 (95% CI 21.5–24.6), and 16.98 (95% CI 13.1–20.8), respectively (Fig. 1).
In the first model, we compared the incidence rate among individuals who were vaccinated during January and February (Early Vaccinees group) vs. those who were vaccinated during March and April (Late Vaccinees group). We matched 329,177 individuals in each group based on age group (18–39, 40–59, and 60 and over), sex, city of residence, and socioeconomic status (SES). During the follow-up period (between June 1 and July 27), 1911 cases of breakthrough infection were recorded, 1151 of them in the Early Vaccinees group and 760 in the Late Vaccinees group. After adjustment for underlying comorbidities, we found a statistically significant 51% (95% CI 40–68%) increased risk for breakthrough infection in Early Vaccinees (P < 0.001) (Table 1; Model 1, Fig. 2). When stratifying the results by age, we found a similar trend across all age groups. In addition, there was a non-significant trend of increased hospitalizations with 15 and 4 in the Early and Late Vaccine groups, respectively (HR = 2.4, 95% CI 0.8–6.7) (Fig. 2). In the second model, we compared each month separately by including individuals according to the month in which they considered fully vaccinated and found higher risks for breakthrough infections in those who were vaccinated Early compared with late in each month-group (Table 1, Model 2). Individuals who were vaccinated in January 2021 had a 2.26-fold increased risk (95% CI 1.80–3.01) for breakthrough infection compared to individuals who were vaccinated in April 2021 (Table 1).
In this cohort of MHS members, all of whom are vaccinated with the BioNTech/Pfizer mRNA BNT162b2 vaccine in a two-dose regimen, we identified a significant correlation between time-from-vaccine and afforded protection against SARS-CoV-2 infection. The risk for breakthrough infection was significantly higher for Early Vaccinees compared with those vaccinated later with an additional trend for higher risk for hospitalization among the Early Vaccinees group. Our results correspond to recent publications that demonstrate a significant decline in antibody levels and immune systems compounds over time following the second dose of vaccination5,6,7.
Our study has several important limitations. First, as the Delta variant was the dominant strain in Israel during the study period, the observed decrease in long-term protection afforded by the vaccine against other strains cannot be inferred. Second, as we excluded participants with previous infections and the longer time intervals between the two doses, our study cannot assess the effectiveness of these two factors on breakthrough infection and the results may not be generalizable to settings where an extended dosing interval was applied. At last, the results might be affected by differences between the groups in terms of health behaviors (such as social distancing and mask-wearing), a possible confounder that was not assessed. Our adjustment of PCR test frequency mitigated some of the potential bias of testing behavior. As chronically ill patients were given priority for vaccination, confounding by indication should be considered when interpreting the study results; nonetheless, adjusting for obesity, cardiovascular disease, diabetes, hypertension, chronic kidney disease, cancer, chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), and immunosuppression had only a small impact on the estimate of effect as compared with the unadjusted HR (unadjusted results are provided in Supplementary Table 1). Therefore, residual confounding by unmeasured factors is unlikely.
Taken together, the study suggests a possible relative decrease in the long-term protection of the BNT162b2 vaccine against the Delta variant of SARS-CoV-2. This preliminary finding should be evaluated in future studies, including a comparison to long-term protection against different strains, and prospective clinical trials to examine the effect of a booster vaccine against breakthrough infection.
The study population consisted of all MHS members aged 16 and above who received the second dose of the vaccine between January and April 2021. Individuals were considered fully vaccinated if they received two doses of the BNT162b2, the second one administered within the 21-to-28-day interval set by national guidelines. The minority who did not follow the guidelines included those infected after the first dose or those suffering an intercurrent illness that delayed the administration of the second dose.
Individuals were excluded from the study if they had a positive SARS-CoV-2 polymerase chain reaction (PCR) assay test result prior to the start of the study period or disengaged from MHS for any reason between January and April. Individual-level data of the study population included age, sex, city of residence, last documented body mass index (Kg/m2) (categorized as normal weight <25, overweight 25–30, and obese >30), and SES, on a scale from 1 (lowest) to 10. SES index is based on several parameters including household income, educational qualifications, household crowding, material conditions, and car ownership. Data collected also included information of chronic diseases from MHS’ automated registries, including cardiovascular diseases16, hypertension, diabetes17, chronic kidney disease18, COPD, IBD, and immunocompromised conditions, as well as data on cancer from the National Cancer Registry19. In addition, dates of the first and second dose of the vaccine (if received), count, and results of any PCR tests for SARS-CoV-2, all recorded centrally in MHS, were included in the analysis.
To assess the correlation between time-from-vaccine and afforded protection against breakthrough infection, two Cox proportional hazards regression models were applied. In both models, the outcome was defined as a positive SARS-CoV-2 PCR test recorded between June 1st and July 27th, the date of analysis.
In the first model, we addressed the time-from-vaccine by grouping individuals into two separate groups of comparison: Early Vaccinees and Late Vaccinees. We defined Early Vaccinees as individuals who received the second dose of the vaccine between January and February 2021 and Late Vaccinees as individuals who received the second dose between March and April 2021. As the mass vaccination campaign first targeted high-risk individuals (e.g., healthcare personnel and persons with comorbidities) and those over the age of 60, we matched each Early Vaccinee to a Late Vaccinee individual in a 1:1 ratio, based on age group (18–39, 40–59, and 60 and over), sex, city of residence, and socioeconomic status. Results were then adjusted for underlying comorbidities, including obesity, cardiovascular diseases, diabetes, hypertension, chronic kidney disease, cancer, COPD, IBD, and immunosuppression conditions. In addition, the number of PCR tests each individual performed from the beginning of the pandemic until the beginning of the follow-up period was used as a proxy for COVID-19-related health-seeking behavior by adjusting to it as a categorical variable.
In the first model, we additionally applied Cox proportional hazards regression to calculate the Hazard ratio COVID-19-related hospitalizations between the groups.
In the second model, we addressed the time-from-vaccine by analyzing six distinct groups, comparing individuals according to the month in which they were first considered to be fully vaccinated (the groups were January–February, January–March, January–April, February–March, February–April, and March–April). Thereby, we compared the incidence of SARS-CoV-2-breakthrough infection between individuals who were fully vaccinated in January 2021 and those who were fully vaccinated in February 2021 and so on. The same matching and adjustment methods were performed in both models.
Analyses were performed using Python version 3.1 with the stats model package.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.
According to the regulations of the Israel Ministry of Health, individual-level data cannot be shared openly. Specific requests for remote access to de-identified community-level data should be referred to Maccabitech, Maccabi Healthcare Services Institute for Research & Innovation.
Analysis code is available at https://github.com/barakm-ki/Correlation-of-SARS-CoV-2-Breakthrough-Infections-to-Time-from-vaccine.
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2020).
Dagan, N. et al. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1968-1970 (2021).
Chodick, G. et al. The effectiveness of the two-dose BNT162b2 vaccine: analysis of real-world data. Clin. Infect. Dis. https://doi.org/10.1093/CID/CIAB438 (2021).
Seow, J. et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat. Microbiol. 5, 1598–1607 (2020).
Ruopp, M. D., Strymish, J., Dryjowicz-Burek, J., Creedon, K. & Gupta, K. Durability of SARS-CoV-2 IgG antibody among residents in a long-term care community. J. Am. Med. Dir. Assoc. 22, 510–511 (2021).
Shrotri, M. et al. Spike-antibody waning after second dose of BNT162b2 or ChAdOx1. Lancet 398, 385-387 (2021).
Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2109072 (2021).
Liu, Y. et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2106083 (2021).
Wang, P. et al. Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization. bioRxiv, https://doi.org/10.1101/2021.03.01.433466 (2021).
COVID-19 in Israel dashboard. (2021).
Bernal, J. L. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2108891 (2021).
Lustig, Y. et al. Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel. Eurosurveillance 26, 2100557 (2021).
Pfizer CEO says third Covid vaccine dose likely needed within 12 months. https://www.cnbc.com/2021/04/15/pfizer-ceo-says-third-covid-vaccine-dose-likely-needed-within-12-months.html.
Israel offers third shot of Pfizer COVID-19 vaccine to adults at risk | Reuters. https://www.reuters.com/world/middle-east/israel-offers-pfizer-covid-19-vaccine-booster-shots-adults-risk-2021-07-11/.
Shalev, V. et al. The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization. Int. J. Cardiol. 152, 345–349 (2011).
Chodick, G., Heymann, A. D., Shalev, V. & Kookia, E. The epidemiology of diabetes in a large Israeli HMO. Eur. J. Epidemiol. 18, 1143–1146 (2003).
Coresh, J. et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311, 2518–2531 (2014).
Israel Center for Disease Control. Jerusalem, I. Data from: Israel national cancer registry.
There was no external funding for the project.
The authors declare no competing interests.
This study was approved by the MHS Institutional Review Board (MHS-0100-20). Due to the retrospective design of the study, informed consent was waived by the IRB and all identifying details of the participants were removed before computational analysis.
Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Mizrahi, B., Lotan, R., Kalkstein, N. et al. Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine. Nat Commun 12, 6379 (2021). https://doi.org/10.1038/s41467-021-26672-3